Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
The Bcr-Abl kinase inhibitor imatinib is remarkably effective in chronic myelogenous leukemia (CML), although drug resistance is an emerging problem. Myeloid Src family kinases such as Hck and Lyn are often overexpressed in imatinib-resistant CML cells that lack Bcr-Abl mutations. Here we tested whether Hck overexpression is sufficient to induce imatinib resistance using both wild-type Hck and a mutant (Hck-T338A) that is uniquely sensitive to the pyrazolo-pyrimidine inhibitor, NaPP1. Expression of either kinase in K562 CML cells caused resistance to imatinib-induced apoptosis and inhibition of soft-agar colony formation. Treatment with NaPP1 restored sensitivity to imatinib in cells expressing T338A but not wild-type Hck, demonstrating that resistance requires Hck kinase activity. NaPP1 also reduced Hck-mediated phosphorylation of Bcr-Abl at sites that may affect imatinib sensitivity exclusively in cells expressing Hck-T338A. These data show that elevated Src family kinase activity is sufficient to induce imatinib resistance through a mechanism that may involve phosphorylation of Bcr-Abl.
Pene-Dumitrescu
Teodora
T
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvainia 15219, USA.
Smithgall
Thomas E
TE
D000818:Animals; D017209:Apoptosis; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D008957:Models, Genetic; D009154:Mutation; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology*; D011487:Protein Conformation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D019061:src-Family Kinases / Q000378:metabolism*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; C406060:abl-bcr fusion protein, human; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases
Science. 2000 Sep 15;289(5486):1938-42
10988075
N Engl J Med. 1999 Jul 15;341(3):164-72
10403855
EMBO J. 2002 Nov 1;21(21):5766-74
12411494
J Biol Chem. 1999 Sep 10;274(37):26579-83
10473622
Nat Struct Mol Biol. 2008 Oct;15(10):1109-18
18794843
J Natl Cancer Inst. 2008 Jul 2;100(13):926-39
18577747
J Biol Chem. 2000 Jan 28;275(4):2721-6
10644735
Exp Hematol. 2003 Jun;31(6):504-11
12829026
Science. 2001 Aug 3;293(5531):876-80
11423618
Proc Soc Exp Biol Med. 1981 Apr;166(4):546-50
7194480
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Cell. 1995 Sep 22;82(6):981-8
7553858
J Biol Chem. 2006 Oct 13;281(41):30907-16
16912036
Curr Biol. 1998 Feb 26;8(5):257-66
9501066
Blood. 2003 Jan 15;101(2):690-8
12509383
Cell. 2003 Mar 21;112(6):831-43
12654249
N Engl J Med. 2003 Oct 9;349(15):1451-64
14534339
Blood. 2007 Dec 1;110(12):4055-63
17720881
Genes Dev. 1999 Sep 15;13(18):2400-11
10500097
Cancer Res. 1996 Aug 1;56(15):3589-96
8758931
Oncogene. 1993 Jan;8(1):117-24
7678701
J Biol Chem. 2000 Jun 16;275(24):18581-5
10849448
Chem Biol. 1999 Sep;6(9):671-8
10467133
Oncogene. 2008 Nov 27;27(56):7055-69
18794796
Oncogene. 2002 Nov 21;21(53):8075-88
12444544
Cancer Res. 2008 Dec 1;68(23):9809-16
19047160
J Biol Chem. 2000 Nov 10;275(45):35631-7
10964922
Cell. 1993 Oct 8;75(1):175-85
8402896
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1386-91
19164531
J Mol Biol. 2008 Nov 7;383(2):414-23
18775435
J Biol Chem. 1997 Jul 18;272(29):17899-902
9218412
Mol Cell. 1999 May;3(5):629-38
10360179
Mol Cell. 1999 May;3(5):639-48
10360180
Trends Cell Biol. 2001 Apr;11(4):167-72
11306297
EMBO J. 2002 Feb 15;21(4):514-24
11847100
Nat Struct Biol. 2002 May;9(5):365-9
11976726
Blood. 2008 Apr 1;111(7):3821-9
18235045
Cancer Res. 2004 Jan 15;64(2):672-7
14744784
Cancer Res. 2001 Oct 1;61(19):7318-24
11585772
Cell. 1984 Jan;36(1):93-9
6319012
J Biol Chem. 2006 Sep 15;281(37):27029-38
16849330
J Biol Chem. 2005 Dec 9;280(49):40832-7
16210316
Cancer Res. 2007 Dec 15;67(24):11576-84
18089786
Blood. 2000 Nov 15;96(10):3343-56
11071626
J Mol Biol. 2004 Nov 5;343(5):1255-68
15491611
Cytokine Growth Factor Rev. 1997 Mar;8(1):63-79
9174663
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17456-61
15505216
Nature. 2000 Sep 21;407(6802):395-401
11014197
Chem Biol. 2004 May;11(5):691-701
15157880
Biochim Biophys Acta. 1997 Dec 9;1333(3):F201-16
9426204
Oncogene. 1996 Dec 19;13(12):2589-94
9000132
J Biol Chem. 2001 Mar 2;276(9):6061-4
11152665
J Biol Chem. 1997 Dec 26;272(52):33260-70
9407116
Mol Cell. 2006 Mar 17;21(6):787-98
16543148
Oncogene. 2000 May 15;19(21):2523-31
10851051
Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44
14708008
EMBO J. 1994 Feb 15;13(4):764-73
8112292
Mol Cell Biol. 1991 Apr;11(4):1785-92
2005881
Leukemia. 2002 Nov;16(11):2190-6
12399961
Biochem Biophys Res Commun. 1999 Apr 2;257(1):129-38
10092522
Blood. 2008 Feb 1;111(3):1039-43
17932248
Nature. 1985 Jun 13-19;315(6020):550-4
2989692
Oncogene. 2008 Jun 19;27(27):3831-44
18246120
Oncogene. 2000 Mar 23;19(13):1684-90
10763825
Oncogene. 1996 Feb 15;12(4):839-46
8632906
Bioorg Med Chem. 2005 Apr 15;13(8):2825-36
15781393